Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11714933 | 0.79 | ALDH1A1 (0.35) | CYP3A4ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL30954658 | 0.79 | ALDH1A1 (0.35) | CYP3A4ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL18876082 | 0.76 | ATIC (0.33) | NPC1RAB9A | |
| SCHEMBL6787588 | 0.76 | MAPT (0.39) | ALDH1A1THRBGAADYRK1AMEN1 | |
| SCHEMBL30002759 | 0.76 | GRM4 (0.31) | — | |
| SCHEMBL3648625 | 0.76 | SMN1; SMN2 (0.35) | ALDH1A1TSHRDYRK1ADAO | |
| SCHEMBL6789168 | 0.72 | ELANE (0.39) | MEN1KMT2ANPC1RAB9ADAO | |
| SCHEMBL18876083 | 0.72 | EIF4A3 (0.30) | — | |
| SCHEMBL18876151 | 0.72 | CYP2C19 (0.30) | — | |
| SCHEMBL18876100 | 0.72 | MEN1 (0.33) | MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723741-B2 | ANALGESICS, SEDATIVES, ANESTHETICS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20030105147-A1 | Benzimidazoles and benzothiazoles and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-06-05 | — | — | US | disclosed |
| US-6498177-B2 | ALPHA 2 ADRENERGIC RECEPTOR AGONIST; ANALGESIC, SEDATIVE AND ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020049239-A1 | Novel indole and benzothiazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-04-25 | — | — | US | disclosed |
| US-6303643-B1 | THERAPY OF MIGRAINE HEADACHE, HYPERTENSION, ALCOHOL WITHDRAWAL, DRUG ADDICTION, RHEUMATOID ARTHRITIS, PRESBYOPIA, ISCHEMIC PAIN, SPASTICITY, DIARRHEA, NASAL CONGESTION, AND URINARY INCONTINENCE BY ADMINISTERING BENZOTHIAZOLE DERIVATIVE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-10-16 | — | — | US | disclosed |
| EP-0900080-A4 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6159998-A | Substituted indoles and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| US-6040451-A | USED AS ANALGESIC, SEDATIVE AND ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-21 | — | — | US | disclosed |
| US-5948804-A | ANAESTHETIC PREMEDICATION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0900080-A1 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5677321-A | ANESTHETIC PREMEDICATION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1997031636-A1 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049239-A1 | Novel indole and benzothiazole derivatives | ADRB2, ADRB1, CNR2 | CYP3A4 506/4885ALDH1A1 456/4885THRB 282/4885 |
| US-20030105147-A1 | Benzimidazoles and benzothiazoles and uses thereof | ADRB2, BDKRB2, ADRB1 | CYP3A4 375/4885ALDH1A1 323/4885THRB 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.